UBC proposes to advance cancer research as a priority research area with the recruitment of a President’s Excellence Chair in Precision Oncology.
Precision Oncology will propel leading cancer researchers at the BC Cancer Agency (BCCA), Children & Women’s Health Centre, Vancouver Coastal Health, and collaborators at the Life Sciences Centre and Centre for Drug Research and Development.
The Chair will focus on use of serial sampling to characterize evolution of cancers on treatment to identify and target emerging resistant driver pathways. There is a significant need for biomarkers to help segment cancers, better predict natural history and drug sensitivity, and to minimize futile therapy with expensive drugs that can have variable and modest response rates. Tumor biopsies are invasive, expensive, under-sample tumour heterogeneity, and cannot be serially performed to feasibly monitor tumour evolution over time. Liquid biopsies using circulating tumor cells (CTC) and cell free DNA (cfDNA) promise an alternative, scalable approach to complement serial biopsies, providing insights to mechanisms of progression and therapeutic resistance while guiding development of treatment strategies.
We plan to recruit a clinician scientist, who is an oncologist with overlapping expertise in genomics, clinical trials research, novel drug development, and experienced in precision oncology to fill the position of the UBC President’s Excellence Chair in Precision Oncology. The Chair is open to any outstanding individual who fits the criteria of not only being a leader in genomics and precision oncology, but also the champion who would grow much needed medical leadership to support growing needs in precision oncology at UBC and BCCA, enabling a structured approach to integrate cancer genomics in clinical trials and generate high quality knowledge that will ultimately lead to improved outcomes for cancer patients.
Integration across genomics, informatics, treatment science, biomarkers (in particular tissue based and cfDNA genomic testing), and novel drug development are required to help support many disease site programs at the BCCA, as well as successful growth of umbrella trials that are now being developed and led across the country by BCCA and other academic partners.
To apply, please view the full position recruitment advertisement below:
For additional information please contact: